In the initial hyperinflammatory phase of sepsis, induction of MTF by LPS results in the development of DIC by activation of factor VII followed by factor X and IX (Rivers et al, 1992) . However, DIC surviving patients then become immunosuppressed or 'immunoparalysed' (Volk et al, 1996; Astiz et al, 1996) , which is characterized by the presence of unresponsive monocytes, T cells, NK cells, and an increased rate of immune cell apoptosis (Ayala & Chaudry, 1996) . A preponderance of IL-10 occurs in the plasma of human sepsis patients, and is also present in affected organs of mice (van der Poll et al, 1997b (van der Poll et al, , 1995 . Recently, the use of antiinflammatory cytokines has been studied in vitro, to demonstrate their down-regulatory effects on LPS-induced MTF mRNA transcription, protein expression, and procoagulant activity (PCA), chiefly by IL-10 treatment (also IL-4, IL-13 and TGF-b; Ramani et al, 1993a, b; Pradier et al, 1993; Jungi et al, 1994) . IL-10 dose-dependent inhibitions of LPSinduced MTF and PCA in isolated mononuclear cell (MNC) cultures has shown that >5 ng/ml caused a >90% inhibition of MTF or PCA (Ramani et al 1993a; Pradier et al, 1993; Ernofsson et al, 1996) , whereas delaying the addition of IL-10 (1 h after LPS) resulted in a reduced inhibition of MTF expression to 68% (Ernofsson et al, 1996) .
A recent in vivo study employing normal human volunteers has confirmed the in vitro findings that prior or simultaneous treatment with IL-10 almost abrogates the procoagulant and fibrinolytic responses to LPS challenge (Pajkrt et al, 1997) . Delayed treatment with IL-10 (1 h after LPS) only partially, but significantly, reduced the procoagulant response, but not the fibrinolytic response (Pajkrt et al, 1997) . Previous studies employing a mouse model of severe peritonitis showed that delayed delivery of IL-10 (6 h) after sepsis induction decreased lethality (Kato et al, 1995) .
All these anti-inflammatory treatment regimes aim at intervening in the septic process very early, to inhibit the adverse effects of tissue factor (TF) exposure in peripheral whole blood. The avoidance of the hyperinflammatory phase of sepsis (characterized by an increase in PCA) may also reduce or abrogate the development of the immunoparalysis phase of the disease (Volk et al, 1996) . The lack of complete inhibition of the LPS-induced procoagulant response when IL-10 treatment is delayed may be due to the action of platelets, lymphocytes or granulocytes (Østerud, 1992; Edwards & Rickles, 1980; Levy & Edgington, 1980; Halvorsen et al, 1993) . IL-10 down-regulates granulocyte and lymphocyte enhancing procoagulant functions, as well as monocyte anti-inflammatory potential (Niiro et al, 1997; Snijdewint et al, 1993; Faist et al, 1996) . Specifically, IL-10 up-regulates interleukin-1 receptor antagonist (IL-1ra) expression, which increases monocyte anti-inflammatory effectiveness (Moore et al, 1993) , while abrogating LPSinduced cyclooxygenase-2 (COX-2) activity and hence granulocyte prostaglandin E 2 (PGE 2 ) biosynthesis. This causes a reduction of MTF expression and phagocytosis by monocytes and granulocytes (Østerud et al, 1990; Niiro et al, 1997) . Since Th1 helper T-cells are better up-regulators of monocyte PCA than Th2 cells, IL-10 down-regulates MTF expression partly by the switching of the Th1-type cytokine response to Th2 (Del Prete et al, 1995; Snijdewint et al, 1993; Faist et al, 1996) .
Platelets, via P-selectin ligation with Sialyl Lewis X, have been shown to induce MTF and activate monocytes (Halvorsen et al, 1993; Celi et al, 1994; Amirkhosravi et al, 1996; Lo et al, 1997) which may be resistant to the action of IL-10. Previously, we have shown that in MNC cultures, CD28/B7 signalling up-regulates the expression of MTF in initial phases of the response to LPS, although the delayed addition of CD28-blocking antibodies (1 h after LPS) resulted in a significant reduction in the inhibition of MTF expression . This may be as a consequence of the lack of B7 ligation with CD28 (constitutively expressed by 95% of helper T cells), as blockade of B7 by CTLA-4Ig is known to inhibit LPS-induced enhancement of monocyte B7 expression, which is down-regulated by IL-10 (Schmittel et al, 1995; Ding et al, 1993) . The other co-stimulatory signalling pathway, CD40-CD154, has also been shown in mixed MNC reactions to induce the expression of MTF, which is resistant to IL-10 (Pradier et al, 1996) . However, the lack of abrogation of MTF expression by IL-10 (delivered post LPS) may be due to residual low-level monocyte B7 expression.
The aim of this study was to show that IL-10 downregulates MTF expression in an in vitro whole blood model, and that platelet and lymphocyte interactions with monocytes (via P-selectin/Sialyl Lewis X and CD28/B7 signalling) reduces the efficacy of IL-10 in the initial phases of the response to LPS. This may lend support to a modification of the therapeutic use of IL-10 in the treatment of DIC in sepsis. TF, B7.1, B7.2, in whole blood. Whole blood from normal volunteers was collected on separate occasions into Vacutainers containing 3·2% sodium citrate (Becton Dickinson Vacutainer Systems USA, Rutherford, N.J.). Whole blood aliquots (final volume 1 ml) were incubated on a horizontal shaker for 6 h at 37ЊC in 5% CO 2 in 24-flat-well non-adherent tissue culture (TC) plates (Costar, Kennebunk, Maine), with or without 0·01, 0·1, 1 or 10 mg/ml LPS (0111:B4; Sigma Chemical Co., St Louis, Mo.).
MATERIALS AND METHODS

LPS-induced dose-dependent response of monocyte
Monocyte TF, B7.1, B7.2, CD40 and helper T-cell CD154 expression was quantified for each LPS concentration by flow cytometry (see section below).
Regulatory role of monocyte B7 and P-selectin on LPS-induced MTF expression and monocyte/platelet binding in whole blood. Citrated whole blood (1 ml final volume) was incubated with 0·1 mg/ml LPS on a horizontal shaker for 6 h at 37ЊC in 5% CO 2 in the presence of 5 mg/ml recombinant human CTLA-4/Fc chimaera fusion protein (rhCTLA-4Ig; R & D Systems, Minneapolis, Min.), and/or anti-P-Selectin (Endogen, Woburn, Mass.), or IgG 1 murine isotype (R & D Systems, Minneapolis, Min.). Monocyte TF expression and platelet/ monocyte binding was quantified by flow cytometry (see section below).
Dose-dependent effects of IL-10 on LPS-induced monocyte TF, B7.1, B7.2, CD40 and helper T-cell CD154 expression in whole blood. Citrated whole blood (1 ml final volume) was incubated with 0·1 mg/ml LPS on a horizontal shaker for 6 h at 37ЊC in 5% CO 2 in the presence of 0, 0·1, 0·5, 1, 5 or 10 ng/ml recombinant human IL-10 (rhIL-10; R & D Systems, Minneapolis, Min.). For each IL-10 concentration monocyte TF, B7.1, B7.2, CD40 and helper T-cell CD154 expression was quantified by flow cytometry (see section below).
IL-10 down-regulation of LPS-induced MTF expression in whole blood is modulated by LPS-activated platelets and helper T cells.
Citrated whole blood (1 ml final volume) was incubated simultaneously with 0·1 mg/ml LPS and 1 ng/ml rhIL-10 (and 1 h after LPS stimulation) in the presence of rhCTLA-4Ig and/or anti-P-selectin (5 mg/ml; isotype control murine IgG 1 ) on a horizontal shaker for 6 h at 37ЊC in 5% CO 2 . Monocyte TF expression and platelet/monocyte binding was quantified by flow cytometry (see section below).
Flow cytometric determination of monocyte TF, B7.1, B7.2, CD40, helper T-cell CD154 expression and platelet/monocyte binding in whole blood. Incubated whole blood was aliquoted (100 ml) into FACS tubes (Curtin Matheson Scientific Inc., Houston, Texas); MTF was quantitated by incubation with saturating amounts of anti-CD14 PE (5 ml; Immunotech, Marseilles, France) and anti-TF FITC (1 mg; no. 4508CJ; American Diagnostica, Greenwich, Ct.) or anti-IgG 1 FITC (10 ml; Dako, Carpinteria, Calif.) for 20 min at RT; platelet/monocyte binding was quantitated by labelling with anti-CD14 PE and anti-GPIb FITC (20 ml; Immunotech, Marseilles, France). Monocyte B7.1, B7.2, CD40 and helper T-cell CD154 expression were quantitated by labelling whole blood aliquots with 1 mg anti-B7.1 (Immunotech, Marseilles, France), anti-B7.2 (Serotec, Raleigh, N.C.), anti-CD40 (Immunotech), anti-CD154 (Immunotech) or IgG 1 isotype control (Immunotech) at room temperature (RT) for 20 min. Aliquots of 2 ml Tris-0·83% ammonium chloride lyse (0·01M; Sigma), pH 7·4, were then incubated with labelled whole blood at 37ЊC for 20 min. Aliquots for quantitation of MTF and platelet/ monocyte binding were then washed twice in PBS and resuspended in 250 ml PBS with 0·25% paraformaldehyde (PFA; Sigma). Monocytes labelled with B7.1, B7.2 and CD40 (or isotype) and helper T cells (labelled with CD154 or isotype) were washed once in PBS and then incubated with 0·5 mg goat anti-mouse conjugated with RED-613 (Gibco BRL, Paisley, Scotland) at RT for 20 min. After a further wash in PBS, the monocyte tubes (plus isotype) were incubated with anti-CD14 PE , with CD154-labelled T cells (plus isotype) incubated with 10 ml CD3 FITC /CD4 PE-Cy5 (Immunotech) at RT for 20 min. After a final PBS wash, samples were resuspended in 250 ml PBS with 0·25% PFA.
Two /CD4 PE/Cy-5 positive events. Whole blood was incubated in ultra-low adherent 24-well TC plates for 6 h at 37ЊC at 5% CO 2 (n¼4). Results are expressed as mean Ϯ SEM.
RESULTS
LPS-induced dose-dependent response of MTF, B7.1, B7.2, CD40 and helper T-cell CD154 expression in whole blood
LPS induced MTF expression in a dose-dependent manner (0·01, 0·1, 1 and 10 mg/ml) in citrated whole blood cultures (Figs 2A and 2B ). The induction of MTF (TABC) by LPS ranged from 3·5 to 5·6 × 10 5 (0·01-10 mg/ml); with percentage positive expression of MTF (39-53%) above the baseline control (1·2 × 10 5 TABC; 11·3%; Figs 1A and 1B). Constitutively expressed monocyte B7.2 (Azuma et al, 1993a) was up-regulated by LPS (resting monocytes 1 × 10 5 TABC), plateauing at 10 mg/ml LPS (4·4 × 10 5 TABC; Fig 1A) . The other B7 antigen, B7.1 (induced by LPS; Ding et al, 1993) , was almost zero in the baseline control (1·3 × 10 4 TABC; 0·2% þve) and maximized at 0·1 mg/ml LPS (1·6 × 10 5 TABC; 36·4%; Fig 1B) . LPS at higher concentrations (1 and 10 mg/ml) resulted in a lower expression of B7.1 (0·75 × 10 5 TABC, 21·5% and 0·7 × 10 5 TABC, 17% respectively). Monocyte CD40 up-regulation by LPS peaked at 0·01 mg/ml (1·8 × 10 5 TABC; 56%) from a baseline (0·9 × 10 8 TABC; 26%) and falling at the higher concentrations of LPS (1·2 × 10 5 TABC; 37% for 10 mg/ml LPS; Fig 1C) .
The ligand for CD40 expressed by activated helper T cells, CD154 (previously designated CD40L) was present on resting helper T cells in very low amounts (1·3 × 10 5 TABC, 0·2% þve, Fig 1D) . The percentage of helper T cells expressing CD154 peaked at 10% (0·01 mg/ml LPS), and fell dose-dependently (9-3·5%). The CD154 TABC expression was relatively constant for all LPS concentrations, except at 0·1 mg/ml LPS with maximum expression at 6200 TABC (Fig 1D) . The LPS dose-dependent response showed that the high concentration of LPS (0·1 mg/ml) induced relatively high expression of monocyte TF, B7 and helper T-cell CD154 expression, with the exception of CD40 (peaking at 0·01 mg/ml LPS). In the following in vitro MTF downregulation studies the concentration of LPS chosen was 0·1 mg/ml, not only as this gave optimal expression of most co-stimulatory molecules under investigation but allowed comparison to other such studies (Jungi et al, 1994; Ernofsson et al, 1996; Pradier et al, 1996) .
Regulatory role of monocyte B7 and Sialyl Lewis X on LPSinduced MTF expression and monocyte/platelet binding in whole blood
We have previously shown that monocyte B7 and Sialyl Lewis X ligation to helper T-cell CD28 and platelet P-selectin PE events expressing TF FITC or GP FITC (TABC). Whole blood was incubated in ultra-low adherent 24-well TC plates for 6 h at 37ЊC at 5% CO 2 . Results are expressed as mean Ϯ SEM, * P<0·05, ** P<0·01, *** P<0·005, **** P<0·001; NS, not significant (n¼5). up-regulates the MTF response to LPS in a synergistic manner in an isolated cell system . This was repeated in this study using whole blood incubated with LPS (0·1 mg/ml) in the presence of CTLA-4Ig and/or anti-P-selectin (a reported blocking antibody; Fig 3A) . Individually, the blocking agents caused a similar reduction in MTF expression (35%), which was similar to that observed in isolated cell cultures.
However, these blocking agents were not synergistic, contrary to that observed in the isolated cell system, although P-selectin and B7 blockade both affected platelet binding to monocytes (62% and 31% inhibition) with an enhancement of inhibition when both were blockaded (79%; Fig 3B) .
Effect of IL-10 dose-dependent response on LPS-induced monocyte TF, B7.1, B7.2, CD40 and helper T-cell CD154 expression in whole blood
The dose-dependent effects of IL-10 on LPS-induced MTF determined in MNC cultures (Ernofsson et al, 1996) was confirmed in whole blood (Fig 4) . Monocytes expressing TF were reduced in a dose-dependent manner, from 43 Ϯ 3% in the LPS positive control to 24 Ϯ 3% in the presence of 1, 5 and 10 ng/ml IL-10 (P<0·005; Fig 4) . This percentage positive MTF expression determined in whole blood with IL-10 compared very well with the reported inhibitions in MNC cultures (Ernofsson et al, 1996) . The TABC of the monocyte population in such cultures also showed a dose-dependent reduction in MTF expression, with 56% . Whole blood was incubated in ultra-low adherent 24-well TC plates for 6 h at 37ЊC at 5% CO 2 (n¼5). Results are expressed as mean Ϯ SEM, * P<0·05, ** P<0·01, *** P<0·005; NS, not significant. . Whole blood was incubated in ultra-low adherent 24-well TC plates for 6 h at 37ЊC at 5% CO 2 (n ¼ 5). Results are expressed as mean Ϯ SEM, * P<0·05, ** P<0·01, *** P<0·005.
inhibition by 1 ng/ml IL-10, and plateauing to 75% inhibition at the higher concentrations of IL-10 (2·8 Ϯ 0·1 × 10 5 TABC and 2·1 Ϯ 0·3 × 10 5 TABC respectively; P<0·05; Fig 4) . The differences between MNC and whole blood cultures in MTF inhibition by IL-10 may be due to platelet and lymphocyte interactions with LPS-activated monocytes, whereas granulocytes are rendered practically non-functional by IL-10 in terms of their MTF up-regulatory capability (Niiro et al, 1997) .
To explore this possibility further, the expression of LPSinduced B7.1, B7.2, CD40 by monocytes and helper T-cell activation marker CD154 expression were quantitated in the presence of IL-10 in a dose-dependent manner (Figs 5A-D) . B7.1 induction fell to almost zero in the presence of IL-10 (10 ng/ml) (7·7 Ϯ 3·5% positive, 0·31 Ϯ 0·16 × 10 5 TABC) compared to resting monocytes (0·2% positive and 0·1 × 10 5 TABC, <0·05; Fig 5A) . Similar reductions in B7.2 expression (below resting levels) was achieved by IL-10 (0·9 Ϯ 0·4 × 10 5 TABC) compared to resting monocytes (1·6 Ϯ 0·2 × 10 5 TABC; P<0·05; Fig 5B) . The up-regulation of monocyte CD40 by LPS was further enhanced by IL-10, maximally with 0·5 ng/ml (from 1·4 Ϯ 0·1 × 10 5 TABC to 2·7 Ϯ 0·6 × 10 5 TABC), whereas higher IL-10 concentrations caused a lowering in monocyte CD40 expression (P>0·05, Fig 5C) .
The LPS induction of helper T-cell CD154 was inhibited in a dose-dependent manner by IL-10, which is known to modulate T-cell Th0/Th1/Th2 responses (Fig 5D) . Abrogation of CD154 expression occurred at 5 ng/ml IL-10 (0·3 Ϯ 0·2% positive, 390 Ϯ 176 TABC; P<0·05; Fig 5D) .
Efficacy of IL-10 down-regulation of LPS-induced MTF expression in whole blood is reduced by B7 and Sialyl Lewis X ligation
Previous studies showing the in vitro effectiveness of IL-10 to down-regulate MTF expression or PCA has been done in the absence of high numbers of platelets, and the role of lymphocytes excluded by use of adherent monocyte cultures which may have been contaminated with lymphocytes (Ramani et al, 1993a; Pradier et al, 1993; Ernofsson et al, 1996) . Thus, the regulatory effects of B7 and Sialyl Lewis X ligation (mediated by T cells and platelets) on LPS-induced MTF expression may explain the reduced effectiveness of IL-10 in whole blood. The 47% reduction in LPS-induced MTF expression by IL-10 (1 ng/ml; Fig 6A) was significantly enhanced by B7 or P-selectin blockade (P<0·05; Fig 6A) . Together, the blocking agents reduced MTF expression to below that produced by the higher concentrations of IL-10 PE positive events labelled with anti-TF FITC or antiGPIb FITC (n¼5). Whole blood was incubated in ultra-low adherent 24-well TC plates for 6 h at 37ЊC at 5% CO 2 (n¼5). Results are expressed as mean Ϯ SEM, * P<0·05, *** P<0·005; NS, not significant.
Fig 7.
Effect of delayed addition of CTLA-4Ig and/or anti-CD62P (5 mg/ml; n¼5; isotype at 5 mg/ml) and IL-10 (1 ng/ml) on LPSinduced (0·1 mg/ml). (A) MTF expression; (B) platelet:monocyte binding in whole blood quantitated by 'Quantum Simply Cellular TM ' flow cytometry gating on CD14 PE positive events labelled with anti-TF FITC or anti-GPIb FITC (n¼4). Whole blood was incubated in ultralow adherent 24-well TC plates for 6 h at 37ЊC at 5% CO 2 (n¼5). Results are expressed as mean Ϯ SEM, * P<0·05; NS, not significant.
(1·9 Ϯ 0·2 × 10 5 TABC compared to 2·4 Ϯ 0·3 × 10 5 TABC by 10 ng/ml IL-10, P<0·05; Fig 6A) .
The inhibition of platelet/monocyte binding (35%) by P-selectin blockade resulted in a further decrease of MTF expression in the presence of IL-10 (P<0·05; Fig 6B) . This was substantially lower than that determined in the absence of IL-10 (62%; Fig 3B) . Blockade of B7 by CTLA-4Ig fusion protein in the presence of IL-10 did not cause a decrease in platelet/monocyte binding, which was contrary to that observed in the absence of IL-10 (Fig 3B) . Dual blockade of P-selectin and B7 resulted in a further decrease in platelet/ monocyte binding above that observed by P-selectin alone, without effecting expression of MTF (45%; P<0·05; Fig 6B) . Ernofsson et al (1996) employed an isolated cell system and have shown that IL-10 delivered 1 h after LPS caused MTF expression to be 25% higher than when IL-10 was delivered simultaneously with LPS. When IL-10 (1 ng/ml) was added 1 h after LPS in this whole blood model, little difference occurred in MTF expression and platelet:monocyte binding compared to the simultaneous addition of LPS and IL-10 (P<0·05; Figs 7A and 7B). In the simultaneous addition experiments, blockade of P-selectin and/or B7 resulted similar further reductions of MTF expression and plateletmonocyte binding (P<0·05; Figs 7A and 7B ).
Time-dependent efficacy of IL-10 down-regulation of LPS-induced MTF expression in whole blood
DISCUSSION
The therapeutic use of anti-inflammatory cytokines in the treatment of sepsis is aimed at a reduction or abrogation of the expression of TF by monocytes to limit the development of DIC in the initial hyperinflammatory response (Volk et al, 1996) . Recent in vitro and in vivo studies have shown that prior treatment with the anti-inflammatory cytokine, IL-10, before exposure to LPS almost completely negates an increase in MTF expression and end products of PCA (Ernofsson et al, 1996; Pajkrt et al, 1997) . Although the delayed IL-10 treatment (1 h after LPS) caused a significant reduction of MTF expression and the end products of PCA, there was still a significant increase in PCA (Ernofsson et al, 1996; Pajkrt et al, 1997) .
The aims of this study were threefold: (1) to confirm our previous findings of the role of platelet and lymphocyte up-regulation of LPS-induced MTF expression in an in vitro whole blood model; (2) to determine that P-selectin and monocyte B7 blockade enhance the effectiveness of IL-10 after exposure to LPS; and (3) hence propose a modification in the therapeutic use of IL-10 to control DIC in sepsis.
Using our whole blood model, flow cytometric analysis confirmed that LPS up-regulated and induced monocyte B7.2 and B7.1 as well as MTF in a dose-dependent manner (Ding et al, 1993) . The up-regulation by LPS of CD40 on monocytes peaked at a lower concentration of LPS (0·01 mg/ ml) than in the case of B7 (0·1 mg/ml). All co-stimulatory molecules analysed plateaued at the higher LPS concentrations (except MTF). LPS, in this 6 h assay, also induced the expression of the CD40 ligand, CD154, on a small percentage (10%) of helper T cells, indicating the participation of T cells in the initial phase of the response to high concentrations of LPS (0·1 mg/ml). In the IL-10 dose-dependent inhibition of MTF, B7.2, B7.1 and CD154, these high levels of LPS enabled comparison with in vitro isolated cell studies, with optimal expression for co-stimulatory molecules, as well as relatively high expression of MTF (Jungi et al, 1994; Ernofsson et al, 1996; Pradier et al, 1996) .
The MTF regulatory role of platelets and lymphocytes by P-selectin/Sialyl Lewis X and CD28/B7 ligation was confirmed in whole blood (Halvorsen et al, 1993; Celi et al, 1994; Amirkhosravi et al, 1996; Edwards & Rickles, 1980; Levy & Edgington, 1980; . Dual blockade of these antigens did not synergistically inhibit MTF expression, as in the case of isolated cells, but did cause synergistic inhibition of platelet:monocyte binding. The MTF enhancing role of platelets and lymphocytes (and granulocytes) appears to account for the difference in MTF inhibition by IL-10 (5 ng/ml) in whole blood which, at 75%, was lower than that reported previously in isolated cell systems (>90%; Ernofsson et al, 1996) . IL-10 abrogates granulocyte MTF up-regulatory functions by inhibiting COX-2 and up-regulation of IL-1ra expression by monocytes (Niiro et al, 1997; Moore et al, 1993) . However, the effects of IL-10 on platelets have not been reported, and thus may still be fully functional (or partially due to lack of granulocyte interactions) in their ability to up-regulate MTF expression in whole blood (Halvorsen et al, 1993) . LPS (0·1 mg/ml) up-regulation and induction of monocyte B7.1 and B7.2 was down-regulated by IL-10 in a dosedependent manner, with 1-10 ng/ml causing >50% inhibition. Likewise, helper T-cell CD154 induction by LPS was virtually completely inhibited by IL-10 (between 1 and 10 ng/ml). Thus any MTF up-regulatory potential by the CD154 signalling route (which is IL-10 resistant in mixed mononuclear cell reactions), is negated by down-regulation of helper T-cell CD154 expression, even though monocyte CD40 was up-regulated (Pradier et al, 1996) . Furthermore, helper T-cell CD28 expression was unaffected by IL-10 (data not shown; de Waal Malefyt et al, 1993) . Thus CD28-B7 ligation and signalling, if resistant to IL-10, may up-regulate LPS-induced MTF expression.
Consequently, IL-10 (1 ng/ml) with individual and simultaneous blockade of monocyte B7 and platelet P-selectin was chosen to show any enhancement MTF inhibition. Individual blockade caused a further decrease in MTF expression compared to IL-10, whereas the combined blockade acted synergistically to reduce MTF expression below that caused by the higher concentrations of IL-10 (MTF 1·9 Ϯ 0·2 × 10 5 TABC compared to 2·4 Ϯ 0·3 × 10 5 TABC [P<0·05; Fig 5A] ). Thus, residual expression of monocyte B7 and presumably full expression of platelet P-selectin during exposure to IL-10 appeared to be able to up-regulate MTF expression.
Delaying the addition of IL-10 and blocking agents by 1 h resulted in little difference in MTF expression compared to when the cytokine was added simultaneously with LPS. The differences in MTF inhibition observed in the IL-10 dose responses and simultaneous addition experiments (56% compared to 46%), plus higher SEMs in the delayed IL-10 experiments explains the lack of difference observed in MTF expression between simultaneous and delayed addition of IL-10. Furthermore, the delayed addition of IL-10 (1 h after LPS) using MNC cultures resulted in only a 25% increase in MTF expression (Ernofsson et al, 1996) . Given that MTF expression is markedly lower in whole blood models compared to that of isolated MNC, the decrease observed in MTF expression would be small when delaying the addition of IL-10. However, these experiments show that delayed exposure to IL-10 (where B7 expression would be higher), blockade of B7 and P-selectin was still effective in reducing MTF expression to a similar extent as simultaneous addition of IL-10 or the higher concentrations of IL-10.
The effective therapeutic use of anti-inflammatory cytokines or agents that inhibit the inflammatory response in the development of DIC is limited to the early phase of sepsis, with surviving patients later developing an immunoparalysis of the immune system. Recently, it has been shown that antiTNFa, TNF receptor, IL-1ra or IL-1 receptor treatment has little effect in the treatment of sepsis (van der Poll et al, 1994 (van der Poll et al, , 1997a Fisher et al, 1994; Preas et al, 1996) . In murine models, IL-10 has been shown to be effective in the treatment of sepsis, even with a 6 h delay (Kato et al, 1995) . The injection of normal humans with LPS, who are then given IL-10 to counteract the increase in PCA, does not take into account the bacteraemia which occurs in sepsis patients and their requirement to remove these bacteria. High levels of IFNg and IL-12 in the hyperinflammatory stages of the disease are associated with lethal effects (Jansen et al, 1996) . More recently, IFNg treatment has resulted in a high survival rate of patients with immunoparalysis, caused by the reactivation of their cell-mediated immunity (8/9 patients recovered; Docke et al, 1997) . Although IL-10 is autoregulatory (Moore et al, 1993) , treatment of such patients with anti-inflammatory cytokines would be lifethreatening, caused by further suppression of the immune system and abrogation of phagocytosis, which presumably would seriously hinder the patients ability to reduce bacterial load (Ertel et al, 1996) . The high levels of IL-10 detected in non-surviving sepsis patients may limit the usefulness of anti-inflammatory cytokine therapy in long-term sepsis patients (van der Poll et al, 1997b) .
Helper T cells activated at the onset of sepsis would, in the later stages, express B7.2 and B7.1 (Azuma et al, 1993b) . Recent studies have shown that T-cell B7.2 preferentially binds to CTLA-4 which appears to inhibit the T-cell response; with helper T-cell B7.1 binding to both CTLA-4 and CD28 (Greenfield et al, 1997) . Late therapeutic intervention with CTLA-4Ig and IL-10 could also be life-threatening to the patient, due to enhanced inhibition of the helper T-cell response. Conversely, early treatment of sepsis with IFNg may also have lethal effects. Obviously, if very early intervention is possible with anti-inflammatory cytokines (plus B7 blocking agents) this may reduce the probability of the patient reaching the immunoparalysed phase of the disease, which may be clinically beneficial. Thus, it appears necessary to ascertain which stage of sepsis the patient has reached in order to determine which type of therapy, anti-or pro-inflammatory treatment, is suitable.
